InvestSMART

Cleo Diagnostics Ltd (ASX:COV)

ALERT: Price-sensitive ASX Announcement for COV
Current share price for COV : $0.415 -0.185 (-30.83%)+
Announcement
Release
25 Feb 2026 4:24PM
Price at Release
$0.600
Full Release
download
Summary
Cleo Diagnostics Limited reported a significant decrease in revenues for the half-year ending 31 December 2025, amounting to $89,119, which represents a 53.3% drop from the previous period. The company experienced a net loss of $1,983,363, a slight increase from the previous year. No dividends were declared during this period. The company continued its clinical trials in the US and Australia and progressed in securing patents globally for its ovarian cancer detection technology. The equity raised through a December placement amounted to $5 million, bolstering the company’s cash reserves to $9.4 million by the period's end. A Research and Development Tax Incentive contributed $1,717,150 to the company’s income. Cleo Diagnostics also initiated a health economic study, targeting a larger potential market for its Pre-Surgical Ovarian Cancer Test, estimated at over 2 million women annually.
Key Points
  • Revenues decreased by 53.3% to $89,119.
  • Net loss increased to $1,983,363.
  • No dividends declared.
  • Continued clinical trials in the US and Australia.
  • Progress in global patent applications.
  • Equity raised through a $5 million placement.
  • Cash reserves at $9.4 million.
  • Received $1,717,150 from R&D Tax Incentive.
  • Health economic study initiated for a larger market.
  • Potential market estimated at over 2 million women annually.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.